Hepatology News

Researchers have estimated that annual costs associated with alcohol-associated liver disease will climb from $31 billion in 2022 to $66 billion in 2040 — a 118% increase — with costs among women accounting for 43% of the total expenditure.

A “vast majority” of liver transplant centers use stigmatizing language, such as “alcoholic” or “alcohol abuse,” when describing patients with alcohol use disorder and alcohol-associated liver disease on their websites, researchers reported.

Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.

The number one financial goal for most doctors is, by far, getting to a comfortable retirement on their own timeline and with the lifestyle they want.

A Department of Veterans Affairs hepatitis C elimination program was overall successful in getting veterans with hepatitis C to initiate treatment and achieve sustained virologic response, researchers found.

More than 300 million people worldwide, including one in every 10 Americans, are living with a rare disease, yet these individuals and their families are often left isolated and without answers.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.

Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.

Increased intake of dietary niacin may reduce the risk for all-cause mortality but not cardiovascular disease-related mortality among patients with metabolic dysfunction-associated steatotic liver disease, data showed.

An analysis of ED utilization from 2016 to 2019 revealed an increase in visits for alcohol-associated hepatitis, particularly among patients aged 25 to 44 years, as well as an increase in disease severity.